MXPA05009252A - Composicion para el tratamiento de la hepatitis c. - Google Patents

Composicion para el tratamiento de la hepatitis c.

Info

Publication number
MXPA05009252A
MXPA05009252A MXPA05009252A MXPA05009252A MXPA05009252A MX PA05009252 A MXPA05009252 A MX PA05009252A MX PA05009252 A MXPA05009252 A MX PA05009252A MX PA05009252 A MXPA05009252 A MX PA05009252A MX PA05009252 A MXPA05009252 A MX PA05009252A
Authority
MX
Mexico
Prior art keywords
composition
chronic hepatitis
hepatitis
treating
eliminated
Prior art date
Application number
MXPA05009252A
Other languages
English (en)
Inventor
Shuichi Kaneko
Original Assignee
Original Image Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Original Image Co Ltd filed Critical Original Image Co Ltd
Publication of MXPA05009252A publication Critical patent/MXPA05009252A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/286—Carthamus (distaff thistle)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/35—Caprifoliaceae (Honeysuckle family)
    • A61K36/355—Lonicera (honeysuckle)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/68—Plantaginaceae (Plantain Family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Mediante la administracion de una composicion que comprende semilla de calabaza, cartamo, Plantago asiatica L y Lonicera japonica THUMB, los sintomas subjetivos (por ejemplo, malestar general e hinchamiento abdominal) de un paciente con hepatitis C cronica pueden ser eliminados y, ademas, los sintomas objetivos diagnosticados por un medico (por ejemplo, agrandamiento del higado y eritema palmar) pueden ser aliviados o eliminados. De 1 a 3 meses despues de la administracion de la composicion, es gradualmente observada una disminucion significativa en el nivel de ARN del virus de la hepatitis C. Por lo tanto, la composicion anterior es util al menos como una composicion para el tratamiento de la hepatitis C cronica. En particular, esta es ventajosa en el tratamiento de un paciente con hepatitis C cronica que muestra un alto nivel de ARN del virus de la hepatitis C cronica.
MXPA05009252A 2003-03-05 2004-03-04 Composicion para el tratamiento de la hepatitis c. MXPA05009252A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003059056 2003-03-05
PCT/JP2004/002706 WO2004078191A1 (ja) 2003-03-05 2004-03-04 Ｃ型肝炎治療用組成物

Publications (1)

Publication Number Publication Date
MXPA05009252A true MXPA05009252A (es) 2006-03-17

Family

ID=32958817

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05009252A MXPA05009252A (es) 2003-03-05 2004-03-04 Composicion para el tratamiento de la hepatitis c.

Country Status (10)

Country Link
US (1) US7381435B2 (es)
EP (1) EP1609476A4 (es)
JP (1) JPWO2004078191A1 (es)
KR (1) KR100983647B1 (es)
CN (1) CN100531753C (es)
CA (1) CA2517136C (es)
MX (1) MXPA05009252A (es)
TW (1) TWI269656B (es)
WO (1) WO2004078191A1 (es)
ZA (1) ZA200506723B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI322691B (en) * 2003-04-11 2010-04-01 Follicle-stimulating hormone reducing agent
KR100699782B1 (ko) * 2005-07-13 2007-03-27 주식회사 에이치앤케이바이오사이언스 댕댕이나무 추출물을 포함하는 간 기능 회복용 식품 조성물
US20100190968A1 (en) * 2006-10-24 2010-07-29 Bong Cheol Kim Oleanane triterpene saponin compounds which are effective on treatment of dementia and mild cognitive impairment (mci) and improvement of cognitive function
WO2008100547A2 (en) * 2007-02-13 2008-08-21 Ny Financial (International) Corporation Compositions comprising lamiridosin, iridoids or derivatives thereof for treatment of hepatitis c or hepatitis b
AP2011005681A0 (en) 2008-10-02 2011-04-30 George Zabrecky Methods and formulations for treating chronic liver disease.
UA110325C2 (en) * 2009-07-03 2015-12-25 Australian Biomedical Company Pty Ltd Medicinal carbohydrates for treating respiratory conditions
US20120213870A1 (en) * 2011-02-17 2012-08-23 Maher El-Aaser Composition and method for treating liver disease
CN104383541A (zh) 2011-10-21 2015-03-04 艾伯维公司 用于治疗hcv的包含至少两种直接抗病毒剂和利巴韦林但无干扰素的方法
DK2583680T1 (da) 2011-10-21 2015-01-19 Abbvie Inc Mono (PSI-7977) eller kombinationsbehandling af DAA til anvendelse ved behandling af HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CN102641479B (zh) * 2012-05-15 2013-08-21 张治愈 一种治疗丙型肝炎的药物组合物
JP6712056B2 (ja) * 2015-01-23 2020-06-17 株式会社ニューロゲン 肝細胞増殖因子産出誘導剤
CN104800416A (zh) * 2015-04-22 2015-07-29 王玉玲 一种治疗胆囊炎的中药剂
CA3022119A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
CN110772555B (zh) * 2019-12-02 2021-10-12 贵州中医药大学 黄褐毛忍冬不同溶剂提取物在制药中的应用及其制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US445697A (en) 1891-02-03 Gripping device
DE3067048D1 (en) * 1979-12-03 1984-04-19 Kitasato Inst A process for preparing substances having interferon inducing activity and interferon inducers
JPS5697232A (en) * 1979-12-31 1981-08-05 Kitasato Inst:The Interferon inducer and its preparation
EP0030444B1 (en) * 1979-12-03 1985-01-30 Kitasato Kenkyusho A process for preparing substances having interferon inducing activity
JPS5692820A (en) * 1979-12-27 1981-07-27 Kitasato Inst:The Preparation of interferon inducer
JPS5732222A (en) * 1980-08-06 1982-02-20 Kitasato Inst:The Using method of interferon inducer
KR100218052B1 (ko) 1992-07-15 1999-09-01 이병언 B형 간염 바이러스의 복제를 억제하는 약학적 제제
CN1077384A (zh) * 1993-01-20 1993-10-20 吴传福 柳蒲肝防片的制造方法
ZA954785B (en) * 1994-06-16 1996-02-08 Yamanouchi Pharma Co Ltd Crude drug-containing feed
US5648089A (en) * 1995-07-03 1997-07-15 Shawkat; Tarek Extract solution and herbal mixture for treatment of hepatitis
US5837257A (en) * 1996-07-09 1998-11-17 Sage R&D Use of plant extracts for treatment of HIV, HCV and HBV infections
JPH10279491A (ja) * 1997-04-01 1998-10-20 Kao Corp インターロイキン４産生抑制剤
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
JP4204085B2 (ja) * 1997-10-08 2009-01-07 オリジナル・イメージ株式会社 マクロファージ活性化剤
DE19814725A1 (de) * 1998-04-02 1999-10-07 Michael O Ruepp Verwendung von Echinacea-pallida und Echinacea angustifolia-Extrakten; Löwenzahn-/Taraxacum)-Extrakten; Spitzwegerich-(Plantago)-Extrakten
CN1252292A (zh) * 1998-10-27 2000-05-10 王树高 一种治疗肝病的药物
JP4298043B2 (ja) * 1999-03-18 2009-07-15 オリジナル・イメージ株式会社 養魚用飼料
JP2000281584A (ja) * 1999-03-26 2000-10-10 Yamanouchi Pharmaceut Co Ltd 好中球活性化剤
CN1083721C (zh) * 1999-03-29 2002-05-01 首都医科大学附属北京友谊医院 逆转肝纤维化、肝硬化的中药复方及其制备方法
CN1085948C (zh) * 1999-04-23 2002-06-05 全兵杰 一种治疗病毒性肝炎药物的制备方法

Also Published As

Publication number Publication date
EP1609476A8 (en) 2006-04-12
WO2004078191A1 (ja) 2004-09-16
JPWO2004078191A1 (ja) 2006-06-08
CA2517136C (en) 2013-12-24
CN100531753C (zh) 2009-08-26
TWI269656B (en) 2007-01-01
ZA200506723B (en) 2007-01-31
KR20050107490A (ko) 2005-11-11
EP1609476A1 (en) 2005-12-28
TW200425905A (en) 2004-12-01
KR100983647B1 (ko) 2010-09-24
EP1609476A4 (en) 2009-07-01
US7381435B2 (en) 2008-06-03
US20070020348A1 (en) 2007-01-25
CA2517136A1 (en) 2004-09-16
CN1767845A (zh) 2006-05-03

Similar Documents

Publication Publication Date Title
MXPA05009252A (es) Composicion para el tratamiento de la hepatitis c.
EP2397142A3 (en) Use of dpp iv inhibitors
MXPA05006994A (es) Composiciones y metodos para la prevencion y el control de hipoglucemia inducida por insulina.
UA91677C2 (ru) Макроциклические соединения как ингибиторы вирусной репликации
RS53767B1 (en) PROCEDURE FOR TREATMENT OF JOINT INJURY
TNSN08022A1 (en) Novel macrocyclic inhibitors of hepatitis c virus replication
Andronic Prevalence of early loss of primary teeth in 6-10 year old school children in Sibiu
BRPI0415373A (pt) ácidos carboxìlicos macrocìclicos e acilsulfonamidas como inibidores de replicação de hcv
TN2009000481A1 (en) Novel peptide inhibitors of hepatitis c virus replication
ATE430574T1 (de) Medikament auf pflanzlicher basis zur behandlung von hepatitis c
AR013497A1 (es) Terapia en combinacion para erradicar vhc-arn detectable en pacientes que padecen infeccion de hepatitis c cronica
AR049955A1 (es) Composiciones y metodos para el tratamiento de trastornos metabolicos
DE60336934D1 (de) Verwendung von igf-1-serumspiegel-erhöhenden indolessigsäure-derivaten zur herstellung eines arzneimittels zur behandlung von verschiedenen krankheiten
ECSP099427A (es) Barra de Tierra Segunda Generación 16 conexiones
Nowakowska et al. Cytotoxic potential of vasoconstrictor experimental gingival retraction agents-in vitro study on primary human gingival fibroblasts
EA200800397A1 (ru) Композиции тизанидина и способы лечения с применением композиций
HRP20161197T1 (hr) 24-norudca za liječenje autoimunog hepatitisa
RU2010153688A (ru) Режим дозирования телапревира
Blackburn et al. Tamoxifen and liver damage.
ATE466574T1 (de) Verfahren und zusammensetzungen zur oralen fts- abgabe
BR0317095A (pt) Uso de uma combinação contendo um inibidor da transcriptase reversa sem ser de nucleosìdeo (nnrti) com um inibidor citocromo p450, tal como inibidores da protease
AR048806A1 (es) Uso de cariofilenos en la elaboracion de medicamentos y tratamiento de afecciones corporales de inflamacion y dolor inflamatorio
BRPI0410761A (pt) uso de leucina, e, composição para administração entérica a pacientes
Mabiaku Prevalence of supernumerary teeth in a Nigerian population
Tsunada et al. Redox imbalance in the colonic mucosa of ulcerative colitis

Legal Events

Date Code Title Description
FG Grant or registration